

DAFTAR PUSTAKA

- Aini, S.R., Wulandari, L., Andajani, S., 2019. Lung Cancer Patients' Profile in Dr Soetomo General Hospital Surabaya 2016 - 2017: Newest Report. *JUXTA J. Ilm. Mhs. Kedokt. Univ. Airlangga* 10: 44. doi:10.20473/juxta.v10i12019.44-47
- Aliyah, N., Pranggono, E.H., Andriyoko, B., 2016. Kanker Paru: Sebuah Kajian Singkat. *Ina J CHEST Crit Emerg Med* 4: 28–32.
- Amelia, T., Kartasasmita, R.E., Ohwada, T., Tjahjono, D.H., 2022. Structural Insight and Development of EGFR Tyrosine Kinase Inhibitors. *Molecules* 27: 819. doi:10.3390/molecules27030819
- Arumsari, D., Artanti, K.D., Martini, S., Widati, S., 2019. the Description of Smoking Degree Based on Brinkman Index in Patients With Lung Cancer. *J. Berk. Epidemiol.* 7: 249. doi:10.20473/jbe.v7i32019.250-257
- Barria, R.M., 2018. Introductory Chapter: The Contribution of Cohort Studies to Health Sciences, in: Cohort Studies in Health Sciences. InTech, p. 13. doi:10.5772/intechopen.80178
- Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A., Jemal, A., 2018. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA. Cancer J. Clin.* 68: 394–424. doi:10.3322/caac.21492
- Bray, F., Laversanne, M., Sung, H., Ferlay, J., Siegel, R.L., Soerjomataram, I., Jemal, A., 2024. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA. Cancer J. Clin.* 74: 229–263. doi:10.3322/caac.21834
- Butt, Z., Webster, K., Eisenstein, A.R., Beaumont, J., Eton, D., Masters, G.A., Cella, D., 2005. Quality of Life in Lung Cancer: The Validity and Cross-Cultural Applicability of the Functional Assessment of Cancer Therapy–Lung Scale. *Hematol. Oncol. Clin. North Am.* 19: 389–420. doi:10.1016/j.hoc.2005.02.009
- Cappuzzo, F., 2015. Resistance to EGFR TKIs, in: Guide to Targeted Therapies: Treatment Resistance in Lung Cancer. Springer International Publishing, Cham, pp. 27–36. doi:10.1007/978-3-319-20741-4_3
- Cella, D., Eton, D., Fairclough, D., Bonomi, P.D., Heyes, A., Silberman, C., Wolf, M., Johnson, D., 2002. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy–Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. *J. Clin. Epidemiol.* 55: 285–295. doi:10.1016/S0895-4356(01)00477-2
- Cella, D.F., Bonomi, A.E., Lloyd, S.R., Tulsky, D.S., Kaplan, E., Bonomi, P., 1995. Reliability and validity of the functional assessment of cancer therapy—lung (FACT-L) quality of life instrument. *Lung Cancer* 12: 199–220. doi:10.1016/0169-5002(95)00450-F
- Chang, J.W., Huang, C., Fang, Y., Chang, C., Yang, C., Kuo, C.S., Hsu, P., Wu, C., 2023. Epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer harboring uncommon EGFR mutations: Real-world data

- from Taiwan. *Thorac. Cancer* 14: 12–23. doi:10.1111/1759-7714.14537
- Chang, L.-C., Lim, C.-K., Chang, L.-Y., Chen, K.-Y., Shih, J.-Y., Yu, C.-J., 2019. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors. *Eur. J. Cancer* 119: 77–86. doi:10.1016/j.ejca.2019.06.025
- Chen, S., Luster, A.D., 2022. Antihistamines for cancer immunotherapy: More than just treating allergies. *Cancer Cell* 40: 9–11. doi:10.1016/j.ccell.2021.11.007
- Chi, A., Remick, S., Tse, W., 2013. EGFR inhibition in non-small cell lung cancer: Current evidence and future directions. *Biomark. Res.* 1: 6–8. doi:10.1186/2050-7771-1-2
- Dahlan, S., 2014. Analisis Survival : Dasar-Dasar Teori dan Aplikasi Program Stata, 2nd ed. Sagung Seto, Jakarta.
- De Luca, A., Normanno, N., 2010. Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer. *Curr. Drug Targets* 11: 851–864. doi:10.2174/138945010791320773
- Dima, S., Chen, K.-H., Wang, K.-J., Wang, K.-M., Teng, N.-C., 2018. Effect of Comorbidity on Lung Cancer Diagnosis Timing and Mortality: A Nationwide Population-Based Cohort Study in Taiwan. *Biomed Res. Int.* 2018: 1–9. doi:10.1155/2018/1252897
- Direktur Jendral Pencegahan dan Pengendalian Penyakit, 2023. 2023_DitJen P2P_LAKIP sem pertama 2023.pdf. Jakarta.
- Donowati, M.W., Kristin, E., Hutajulu, S.H., Endarti, D., Nindrea, R.D., 2024. The comparative effectiveness of first-line treatment EGFR TKIs in Asian lung cancer population: A systematic review and meta-analysis. *J. Appl. Pharm. Sci.* 14: 53–70. doi:10.7324/JAPS.2024.148324
- Drummond, M.F., 1987. Principles of Economic Appraisal in Health Care. Oxford University Press.
- Drummond, M.F., Sculpher, M.J., Claxton, K., Stoddart, G.L., Torrance, G.W., 2015. Methods for the Economic Evaluation of Health Care Programmes, 4th ed. Oxford University Press.
- Ellison, G., Zhu, G., Moulis, A., Dearden, S., Speake, G., McCormack, R., 2013. EGFR mutation testing in lung cancer: A review of available methods and their use for analysis of tumour tissue and cytology samples. *J. Clin. Pathol.* 66: 79–89. doi:10.1136/jclinpath-2012-201194
- Ettinger, D.S., Wood, D.E., Aisner, D.L., Akerley, W., Bauman, J.R., Bharat, A., Bruno, D.S., Chang, J.Y., Chirleac, L.R., D'Amico, T.A., Dilling, T.J., Dowell, J., Gettinger, S., Gubens, M.A., Hegde, A., Hennon, M., Lackner, R.P., Lanuti, M., Leal, T.A., Lin, J., Loo, B.W., Lovly, C.M., Martins, R.G., Massarelli, E., Morgensztern, D., Ng, T., Otterson, G.A., Patel, S.P., Riely, G.J., Schild, S.E., Shapiro, T.A., Singh, A.P., Stevenson, J., Tam, A., Yanagawa, J., Yang, S.C., 2023. Non-Small Cell Lung Cancer NCCN Evidence Blocks.
- FACIT.org, 1997. Functional Assessment of Cancer Therapy-Lung (FACT-L) questionnaire.
- Fan, H., Shao, Z.Y., Xiao, Y.Y., Xie, Z.H., Chen, W., Xie, H., Qin, G.Y., Zhao,

- N.Q., 2015. Incidence and survival of non-small cell lung cancer in Shanghai: A population-based cohort study. *BMJ Open* 5. doi:10.1136/bmjopen-2015-009419
- Ferlay, J., Colombet, M., Soerjomataram, I., Mathers, C., Parkin, D.M., Piñeros, M., Znaor, A., Bray, F., 2019. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. *Int. J. Cancer* 144: 1941–1953. doi:10.1002/ijc.31937
- Ferlay, J., Colombet, M., Soerjomataram, I., Parkin, D.M., Piñeros, M., Znaor, A., Bray, F., 2021. Cancer statistics for the year 2020: An overview. *Int. J. Cancer* 149: 778–789. doi:10.1002/ijc.33588
- Fitri, N., Yusi, A., Elisna, S., Hesty Utami, R., Tri, K., 2021. Cost-effectiveness analysis of tyrosine kinase inhibitors (erlotinib vs. gefitinib vs. afatinib) in non-small-cell lung cancer. *J. Appl. Pharm. Sci.* 11: 088–095. doi:10.7324/JAPS.2021.110411
- Garattini, L., van de Vooren, K., 2011. Budget impact analysis in economic evaluation: a proposal for a clearer definition. *Eur. J. Heal. Econ.* 12: 499–502. doi:10.1007/s10198-011-0348-5
- Green, J.A., Bates, V., Greenhalgh, J., Boland, A., Jain, P., Dickson, R.C., Dwan, K., Vecchio, F., 2013. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer, in: Green, J.A. (Ed.), *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd, Chichester, UK. doi:10.1002/14651858.CD010383
- Han, J.-Y.Y.J.H., Park, K., Kim, S.-W.W., Lee, D.H., Kim, H.T.H.Y., Kim, H.T.H.Y., Ahn, M.J., Yun, T., Ahn, J.S., Suh, C., Lee, J.W.J.S.J.W.J.-S.S.J.S., Yoon, S.J., Han, J.-Y.Y.J.H., Lee, J.W.J.S.J.W.J.-S.S.J.S., Jo, S.J., Lee, J.W.J.S.J.W.J.-S.S.J.S., 2012. First-SIGNAL: First-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. *J. Clin. Oncol.* 30: 1122–1128. doi:10.1200/JCO.2011.36.8456
- Hanahan, D., Weinberg, R.A., 2011. Hallmarks of Cancer: The Next Generation. *Cell* 144: 646–674. doi:10.1016/j.cell.2011.02.013
- Herbst, R.S., Onn, A., Sandler, A., 2005. Angiogenesis and Lung Cancer: Prognostic and Therapeutic Implications. *J. Clin. Oncol.* 23: 3243–3256. doi:10.1200/JCO.2005.18.853
- Holleman, M.S., Al, M.J., Zaim, R., Groen, H.J.M., Uyl-de Groot, C.A., 2020. Cost-effectiveness analysis of the first-line EGFR-TKIs in patients with non-small cell lung cancer harbouring EGFR mutations. *Eur. J. Heal. Econ.* 21: 153–164. doi:10.1007/s10198-019-01117-3
- Ikawati, Z., 2018. *Farmakologi Molekuler Target Aksi Obat dan Mekanisme Molekularnya*. Gadjah Mada University Press, Yogyakarta.
- ISPOR, I.S.F.P.A.O.R., 2003. *Health Care Cost, Quality, and Outcomes ISPOR Book of Terms*.
- Juliana, F., Jardim, J.R., Fernandes, A.L.G., Jamnik, S., Santoro, I.L., 2010. Reliability of the Brazilian version of the Functional Assessment of Cancer Therapy-Lung (FACT-L) and the FACT-Lung Symptom Index (FLSI). *Clinics* 65: 1247–1251. doi:10.1590/S1807-59322010001200005
- Jusuf, A., Wibawanto, A., Icksan, A.G., Syahrudin, E., Juniarti, Endardjo, S.,

2018. Kanker Paru (Kanker Paru Jenis Karsinoma Bukan Sel Kecil) Pedoman Nasional untuk Diagnosis & Penatalaksanaan di Indonesia 2015, Cetakan Pe. ed. Perhimpunan Dokter Paru Indonesia, Jakarta.
- Kementerian Kesehatan Republik Indonesia, 2023. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MenKes/2197/2023 tentang Formularium Nasional.
- Kementerian Kesehatan Republik Indonesia, 2021. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/6485/2021 tentang Formularium Nasional.
- Kementerian Kesehatan Republik Indonesia, 2018. Salam Sehat! Semoga fakta yang disajikan dalam buku ini, bermanfaat untuk perbaikan perencanaan pembangunan kesehatan, Laporan Rischesdas Nasional 2018.
- Kementerian Kesehatan Republik Indonesia, 2017. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/659/2017 Tentang Formularium Nasional.
- Khiewngam, K., Oranratnachai, S., Kamprerasart, K., Kunakorntham, P., Sanvarinda, P., Trachu, N., Pimsa, P., Wiwitkeyoonwong, J., Thamrongjirapat, T., Dejthevaporn, T., Sirachainan, E., Reungwetwattana, T., 2023. Healthcare coverage affects survival of EGFR-mutant Thai lung cancer patients. *Front. Oncol.* 13: 1–10. doi:10.3389/fonc.2023.1047644
- Koller, M., Hjermstad, M.J., Tomaszewski, K.A., Tomaszewska, I.M., Hornslien, K., Harle, A., Arraras, J.I., Morag, O., Pompili, C., Ioannidis, G., Georgiou, M., Navarra, C., Chie, W.-C., Johnson, C.D., Himpel, A., Schulz, C., Bohrer, T., Janssens, A., Kuliś, D., Bottomley, A., 2017. An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients. *Ann. Oncol.* 28: 2874–2881. doi:10.1093/annonc/mdx453
- Komite Nasional Penyusun Formularium Nasional, 2021. Daftar Obat FORNAS. *Kemenkes RI*.
- Komite Penanggulangan Kanker Nasional, 2017. Pedoman Nasional Pelayanan Kedokteran Kanker Paru, Kementrian Kesehatan Republik Indonesia.
- Komite Penilaian Teknologi Kesehatan, 2017. Buku Panduan Penilaian Teknologi Kesehatan.
- Kristin, E., 2019. Penilaian Teknologi Terapetik (Health Technology Assessment in Therapy) Di Era Jaminan Kesehatan Nasional.
- Kristin, E., Endarti, D., Anggriani, Y., Setiawan, E., Siahaan, S.A.S., Setiaji, R., Amelia, D., Viaza, E., Hermawan, H., Badjongga, J.W., Putra, R.S., Yeni, Donimando, I.S., Asfar, A.I., 2016. Pedoman Teknis Analisis Farmakoekonomi Di Fasilitas Kesehatan. Kementrian Kesehatan Republik Indonesia.
- Lee, S.H., Kim, E.Y., Kim, A., Chang, Y.S., 2020. Clinical implication and usefulness of de novo EGFR T790M mutation in lung adenocarcinoma with EGFR-tyrosine kinase inhibitor sensitizing mutation. *Cancer Biol. Ther.* 21: 741–748. doi:10.1080/15384047.2020.1776579
- Leelahavarong, P., 2014. Budget impact analysis. *J. Med. Assoc. Thai.* 97 Suppl 5: S65-71.
- Lemeshow, S. (University of M., Hosmer Jr, D.W. (University of M., Klar, J.

- (University of M., Lwanga, S.K. (World H.O., 1990. Adequacy of Sample Size in Health Studies. John Wiley and Sons Ltd.
- Limwattananon, C., Limwattananon, S., Waleekhachonloet, O., Rattanachotphanit, T., 2018. Cost-effectiveness analysis of policy options on first-line treatments for advanced, non-small cell lung cancer in Thailand. *Lung Cancer* 120: 91–97. doi:10.1016/j.lungcan.2018.04.003
- Luce, B.R., Drummond, M., Jonsson, B., Neumann, P.J., Schwartz, J.S., Siebert, U., Sullivan, S.D., 2010. EBM, HTA, and CER: Clearing the Confusion. *Milbank Q.* 88: 256–276. doi:10.1111/j.1468-0009.2010.00598.x
- Maemondo, M., Inoue, A., Kobayashi, K., Sugawara, S., Oizumi, S., Isobe, H., Gemma, A., Harada, M., Yoshizawa, H., Kinoshita, I., Fujita, Y., Okinaga, S., Hirano, H., Yoshimori, K., Harada, T., Ogura, T., Ando, M., Miyazawa, H., Tanaka, T., Saijo, Y., Hagiwara, K., Morita, S., Nukiwa, T., 2010. Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR. *N. Engl. J. Med.* 362: 2380–2388. doi:10.1056/NEJMoa0909530
- Menteri Kesehatan Republik Indonesia, 2019. Keputusan Menteri Kesehatan Republik Indonesia Nomor HK.01.07/MENKES/813/2019 Tentang Formularium Nasional.
- Menteri Kesehatan Republik Indonesia, 2013. Keputusan Menteri Kesehatan Republik Indonesia Nomor 328/MENKES/IX/2013 Tentang Formularium Nasional.
- Midha, A., Dearden, S., McCormack, R., 2015. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). *Am. J. Cancer Res.* 5: 2892–911.
- Mok, T.S., Cheng, Y., Zhou, X., Lee, K.H., Nakagawa, K., Niho, S., Chawla, A., Rosell, R., Corral, J., Migliorino, M.R., Pluzanski, A., Noonan, K., Tang, Y., Pastel, M., Wilner, K.D., Wu, Y.-L., 2021. Updated Overall Survival in a Randomized Study Comparing Dacomitinib with Gefitinib as First-Line Treatment in Patients with Advanced Non-Small-Cell Lung Cancer and EGFR-Activating Mutations. *Drugs* 81: 257–266. doi:10.1007/s40265-020-01441-6
- Nair, G., Iyer, A., 2013. Lung cancer - Where are we now? *Journal, Indian Acad. Clin. Med.* 14: 50–56.
- Ng, W.-W., Lin, C.-C., Cheng, C.-Y., Jiang, J.-S., Kao, S.-J., Yeh, D.Y., 2021. Real-world outcomes of first- and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: A retrospective observational cohort study. *PLoS One* 16: e0253335. doi:10.1371/journal.pone.0253335
- Novikov, N.M., Zolotaryova, S.Y., Gautreau, A.M., Denisov, E. V., 2021. Mutational drivers of cancer cell migration and invasion. *Br. J. Cancer* 124: 102–114. doi:10.1038/s41416-020-01149-0
- Okimoto, R.A., Bivona, T.G., 2014. Recent advances in personalized lung cancer medicine. *Per. Med.* 11: 309–321. doi:10.2217/pme.14.19
- Oser, M.G., Niederst, M.J., Sequist, L. V., Engelman, J.A., 2015. Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. *Lancet Oncol.* 16: e165–e172. doi:10.1016/S1470-

2045(14)71180-5

- Otsuka, T., Mori, M., Yano, Y., Uchida, J., Nishino, K., Kaji, R., Hata, A., Hattori, Y., Urata, Y., Kaneda, T., Tachihara, M., Imamura, F., Katakami, N., Negoro, S., Morita, S., Yokota, S., 2015. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212). *Anticancer Res.* 35: 3885–91.
- Paola M. Soccal, M.P., 2013. Cytopathological Diagnosis of Non Small Cell Lung Cancer: Recent Advances Including Rapid On-Site Evaluation, Novel Endoscopic Techniques and Molecular Tests. *J. Pulm. Respir. Med.* doi:10.4172/2161-105X.S5-002
- Paracha, N., Abdulla, A., MacGilchrist, K.S., 2018. Systematic review of health state utility values in metastatic non-small cell lung cancer with a focus on previously treated patients. *Health Qual. Life Outcomes* 16: 179. doi:10.1186/s12955-018-0994-8
- Park, K., Tan, E.-H., O’Byrne, K., Zhang, L., Boyer, M., Mok, T., Hirsh, V., Yang, J.C.-H., Lee, K.H., Lu, S., Shi, Y., Kim, S.-W., Laskin, J., Kim, D.-W., Arvis, C.D., Kölbeck, K., Laurie, S.A., Tsai, C.-M., Shahidi, M., Kim, M., Massey, D., Zazulina, V., Paz-Ares, L., 2016. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial. *Lancet Oncol.* 17: 577–589. doi:10.1016/S1470-2045(16)30033-X
- Park, S., Lee, S.Y., Kim, D., Sim, Y.S., Ryu, J.-S., Choi, J., Lee, S.H., Ryu, Y.J., Lee, J.H., Chang, J.H., 2021. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types. *BMC Cancer* 21: 52. doi:10.1186/s12885-020-07765-6
- Paz-Ares, L., Tan, E.H., O’Byrne, K., Zhang, L., Hirsh, V., Boyer, M., Yang, J.C.H., Mok, T., Lee, K.H., Lu, S., Shi, Y., Lee, D.H., Laskin, J., Kim, D.W., Laurie, S.A., Kölbeck, K., Fan, J., Dodd, N., Märten, A., Park, K., 2017. Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial. *Ann. Oncol.* 28: 270–277. doi:10.1093/annonc/mdw611
- Plużański, A., Piórek, A., 2016. Side effects of tyrosine kinase inhibitors — management guidelines. *Oncol Clin Pr.* 12: 113–118. doi:10.5603/OCP.2016.0004
- Prasetyo, S.J., Soeroso, N.N., Tarigan, S.P., Mutiara, E., Faizah, N.N., 2023. Survival Analysis of Lung Adenocarcinoma Patients with Exon 19 Del and 21 L858R Mutations Receiving EGFR-TKI Treatment. *J. Respirasi* 9: 101–107. doi:10.20473/jr.v9-I.2.2023.101-107
- PubChem, 2021. Compound Summary.
- Purba, F.D., Hunfeld, J.A.M., Iskandarsyah, A., Fitriana, T.S., Sadarjoen, S.S., Ramos-Goñi, J.M., Passchier, J., Busschbach, J.J. V., 2017. The Indonesian EQ-5D-5L Value Set. *Pharmacoeconomics* 35: 1153–1165. doi:10.1007/s40273-017-0538-9

- Ramalingam, S.S., Jänne, P.A., Mok, T., O'Byrne, K., Boyer, M.J., Von Pawel, J., Pluzanski, A., Shtivelband, M., Docampo, L.I., Bennouna, J., Zhang, H., Liang, J.Q., Doherty, J.P., Taylor, I., Mather, C.B., Goldberg, Z., O'Connell, J., Paz-Ares, L., 2014. Dacomitinib versus erlotinib in patients with advanced-stage, previously treated non-small-cell lung cancer (ARCHER 1009): a randomised, double-blind, phase 3 trial. *Lancet Oncol.* 15: 1369–1378. doi:10.1016/S1470-2045(14)70452-8
- Reck, M., Popat, S., Reinmuth, N., De Ruysscher, D., Kerr, K.M., Peters, S., 2014. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann. Oncol.* 25: iii27–iii39. doi:10.1093/annonc/mdu199
- Registry, C., 2020. Interm Result per January 2020 Yogyakarta Cancer Registry.
- Sahrn, S., Wulandari, L., 2019. Case report: Management of Progressive Lung Cancer Patients after First-Line EGFR Tyrosine Kinase Inhibitor Therapy. *Folia Medica Indones.* 55: 239. doi:10.20473/fmi.v55i3.15509
- Sari, L., Purwanto, 2016. Mutasi EGFR pada Non-Small Cell Lung Cancer di Rumah Sakit Kanker “Dharmas.” *Indones. J. Cancer* 10: 131–136.
- Sari, S., Andayani, T.M., Endarti, D., Widayati, K., 2022. Cost-Effectiveness Analysis of Afatinib versus Gefitinib in Non-small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Mutation in Indonesia: Observational studies with Retrospectives. *Res. J. Pharm. Technol.* 15: 1598–1602. doi:10.52711/0974-360X.2022.00267
- Sari, S., Andayani, T.M., Endarti, D., Widayati, K., 2020. Health-Related Quality of Life in Non-Small Cell Lung Cancer (NSCLC) Patients with Mutation of Epidermal Growth Factor Receptor (EGFR) in Indonesia. *Res. J. Pharm. Technol.* 13: 443. doi:10.5958/0974-360X.2020.00086.4
- Sari, S., Andayani, T.M., Endarti, D., Widayati, K., 2019. Effectiveness of afatinib and gefitinib in non-small cell lung cancer (NSCLC) epidermal growth factor receptor (EGFR) mutations in Indonesia: Observational studies with retrospectives. *Int. J. Res. Pharm. Sci.* 10: 3516–3522. doi:10.26452/ijrps.v10i4.1727
- Sato, M., Shames, D.S., Girard, L., Gazdar, A.F., Minna, J.D., 2008. Molecular Basis of Lung Cancer, in: *The Molecular Basis of Cancer*. Elsevier, pp. 397–407. doi:10.1016/B978-141603703-3.10030-5
- Setiawan, D., Endarti, D., Suwantika, A.A., 2017. *Farmakoekonomi Modeling*, Cetakan Ke. ed. UM Purwokerto Press.
- Setyawan, U.A., Tantular, R., Bahar, C., 2023. Survival Rate of Lung Adenocarcinoma Patients Receiving EGFR - Tyrosine Kinase Inhibitor Targeted Therapy. *J. Kedokt. Brawijaya* 32: 165–170. doi:10.21776/ub.jkb.2022.032.03.5
- Shea, M., Costa, D.B., Rangachari, D., 2016. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches. *Ther. Adv. Respir. Dis.* 10: 113–129. doi:10.1177/1753465815617871
- Shi, Y., Zhang, L., Liu, X., Zhou, C., Zhang, L., Zhang, S., Wang, D., Li, Q., Qin, S., Hu, C., Zhang, Y., Chen, J., Cheng, Y., Feng, J., Zhang, H., Song, Y., Wu,

- Y.-L., Xu, N., Zhou, J., Luo, R., Bai, C., Jin, Y., Liu, W., Wei, Z., Tan, F., Wang, Y., Ding, L., Dai, H., Jiao, S., Wang, J., Liang, L., Zhang, W., Sun, Y., 2013. Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial. *Lancet Oncol.* 14: 953–961. doi:10.1016/S1470-2045(13)70355-3
- Skinner, K.E., Fernandes, A.W., Walker, M.S., Pavilack, M., VanderWalde, A., 2018. Healthcare costs in patients with advanced non-small cell lung cancer and disease progression during targeted therapy: a real-world observational study. *J. Med. Econ.* 21: 192–200. doi:10.1080/13696998.2017.1389744
- Soda, M., Choi, Y.L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.I., Watanabe, H., Kurashina, K., Hatanaka, H., Bando, M., Ohno, S., Ishikawa, Y., Aburatani, H., Niki, T., Sohara, Y., Sugiyama, Y., Mano, H., 2007. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. *Nature* 448: 561–566. doi:10.1038/nature05945
- Soo, R., Mery, L., Bardot, A., Kanessvaran, R., Keong, T.C., Pongnikorn, D., Prasongsook, N., Hutajulu, S.H., Irawan, C., Manan, A.A., Thiagarajan, M., Sripan, P., Peters, S., Storm, H., Bray, F., Stahel, R., 2022. Diagnostic work-up and systemic treatment for advanced non-squamous non-small-cell lung cancer in four Southeast Asian countries. *ESMO open* 7: 100560. doi:10.1016/j.esmoop.2022.100560
- Stahel, R.A., Peters, S., Garassino, M.C. (Eds.), 2019. Thoracic Tumours Essentials for Clinicians, Second ed. ed. ESMO Press.
- Su, V.Y.-F., Yang, K.-Y., Huang, T.-Y., Hsu, C.-C., Chen, Y.-M., Yen, J.-C., Chou, Y.-C., Chang, Y.-L., He, C.-H., 2020. The efficacy of first-line tyrosine kinase inhibitors combined with co-medications in Asian patients with EGFR mutation non-small cell lung cancer. *Sci. Rep.* 10: 14965. doi:10.1038/s41598-020-71583-w
- Sullivan, S.D., Mauskopf, J.A., Augustovski, F., Jaime Caro, J., Lee, K.M., Minchin, M., Orlewska, E., Penna, P., Rodriguez Barrios, J.-M., Shau, W.-Y., 2014. Budget Impact Analysis—Principles of Good Practice: Report of the ISPOR 2012 Budget Impact Analysis Good Practice II Task Force. *Value Heal.* 17: 5–14. doi:10.1016/j.jval.2013.08.2291
- Sunami, K., Furuta, K., Tsuta, K., Sasada, S., Izumo, T., Nakaoku, T., Shimada, Y., Saito, M., Nokihara, H., Watanabe, S., Ohe, Y., Kohno, T., 2016. Multiplex Diagnosis of Oncogenic Fusion and MET Exon Skipping by Molecular Counting Using Formalin-Fixed Paraffin Embedded Lung Adenocarcinoma Tissues. *J. Thorac. Oncol.* 11: 203–212. doi:10.1016/j.jtho.2015.10.005
- Sung, H., Ferlay, J., Siegel, R.L., Laversanne, M., Soerjomataram, I., Jemal, A., Bray, F., 2021. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA. Cancer J. Clin.* 71: 209–249. doi:10.3322/caac.21660
- Supabphol, S., Seubwai, W., Wongkham, S., Saengboonmee, C., 2021. High glucose: an emerging association between diabetes mellitus and cancer progression. *J. Mol. Med.* 99: 1175–1193. doi:10.1007/s00109-021-02096-w
- Sutandyo, N., Hanafi, A., Jayusman, M., 2019. Comparison of Effectiveness of Gefitinib, Erlotinib, and Afatinib in Advanced Non-small Cell Lung Cancer

- Patients with EGFR Mutation Positive in Indonesian Population]. *Zhongguo Fei Ai Za Zhi* 22: 562–567. doi:10.3779/j.issn.1009-3419.2019.09.02
- Sutandyo, N., Suratman, E., 2018. Non-Small Cell Lung Carcinoma in Women: A Retrospective Cohort Study in Indonesia. *Acta Med. Indones.* 50: 291–298.
- Syahrudin, E., Wulandari, L., Sri Muktiati, N., Rima, A., Soeroso, N., Ermayanti, S., Levi, M., Hidajat, H., Widjajahakim, G., Utomo, A., 2018. Uncommon EGFR mutations in cytological specimens of 1,874 newly diagnosed Indonesian lung cancer patients. *Lung Cancer Targets Ther.* Volume 9: 25–34. doi:10.2147/LCTT.S154116
- Syahrudin, E., Zaini, J., Soehardiman, D., Aniwidyaningsih, W., Icksan, A.G., Mety, S.H., Pratomo, I.P., 2019. Pedoman Penstagingan Dan Pengevaluasian Hasil Terapi di Indonesia, Edisi 2019. ed. Perhimpunan Dokter Paru Indonesia, Jakarta.
- Tam, K., Daly, M., Kelly, K., 2017. Treatment of Locally Advanced Non-Small Cell Lung Cancer. *Hematol. Oncol. Clin. North Am.* 31: 45–57. doi:10.1016/j.hoc.2016.08.009
- Tan, P.-T., Aziz, M.I.A., Pearce, F., Lim, W.-T., Wu, D.B.-C., Ng, K., 2018. Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer's perspective. *BMC Cancer* 18: 352. doi:10.1186/s12885-018-4223-y
- The Cancer Genome Atlas Research Network, 2014. Comprehensive molecular profiling of lung adenocarcinoma. *Nature* 511: 543–550. doi:10.1038/nature13385
- Tsimberidou, A.M., Elkin, S., Dumanois, R., Pritchard, D., 2020. Clinical and Economic Value of Genetic Sequencing for Personalized Therapy in Non-small-cell Lung Cancer. *Clin. Lung Cancer* 21: 477–481. doi:10.1016/j.clcc.2020.05.029
- Wahidin, M., Noviani, R., Hermawan, S., Andriani, V., Ardian, A., Djarir, H., 2012. Population-Based Cancer Registration in Indonesia. *Asian Pacific J. Cancer Prev.* 13: 1709–1710. doi:10.7314/APJCP.2012.13.4.1709
- Warburg, O., 1956. On the Origin of Cancer Cells. *Science (80-)*. 123: 309–314. doi:10.1126/science.123.3191.309
- WHO, I., 2019. Indonesia, Country-specific Report.
- World Health Organization (WHO), 2024. Global cancer burden growing , amidst mounting need for services [WWW Document]. *Int. Agency Res. Cancer.* URL <https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services>
- Wu, Y.-L., Cheng, Y., Zhou, X., Lee, K.H., Nakagawa, K., Niho, S., Tsuji, F., Linke, R., Rosell, R., Corral, J., Migliorino, M.R., Pluzanski, A., Sbar, E.I., Wang, T., White, J.L., Nadanaciva, S., Sandin, R., Mok, T.S., 2017. Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial. *Lancet Oncol.* 18: 1454–1466. doi:10.1016/S1470-2045(17)30608-3
- Wu, Y.-L., Zhou, C., Liam, C.-K., Wu, G., Liu, X., Zhong, Z., Lu, S., Cheng, Y.,

- Han, B., Chen, L., Huang, C., Qin, S., Zhu, Y., Pan, H., Liang, H., Li, E., Jiang, G., How, S.H., Fernando, M.C.L., Zhang, Y., Xia, F., Zuo, Y., 2015. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. *Ann. Oncol.* 26: 1883–1889. doi:10.1093/annonc/mdv270
- Wulandari, L., Febriani, A., Fatmawati, F., Soegiarto, G., 2018. Evaluation of Patients with Lung Cancer Treated with Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor. *Asian J. Oncol.* 04: 048–053. doi:10.1055/s-0038-1676872
- Yang, J.C.H., Hirsh, V., Schuler, M., Yamamoto, N., O’Byrne, K.J., Mok, T.S.K., Zazulina, V., Shahidi, M., Lungershausen, J., Massey, D., Palmer, M., Sequist, L. V., 2013. Symptom control and quality of life in lux-lung 3: A phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. *J. Clin. Oncol.* 31: 3342–3350. doi:10.1200/JCO.2012.46.1764
- Yang, J.J., Zhou, Q., Yan, H.H., Zhang, X.C., Chen, H.J., Tu, H.Y., Wang, Z., Xu, C.R., Su, J., Wang, B.C., Jiang, B.Y., Bai, X.Y., Zhong, W.Z., Yang, X.N., Wu, Y.L., 2017. A phase III randomised controlled trial of erlotinib vs gefitinib in advanced non-small cell lung cancer with EGFR mutations. *Br. J. Cancer* 116: 568–574. doi:10.1038/bjc.2016.456
- Yang, S.-C., Lai, W.-W., Hsu, J.C., Su, W.-C., Wang, J.-D., 2020. Comparative effectiveness and cost-effectiveness of three first-line EGFR-tyrosine kinase inhibitors: Analysis of real-world data in a tertiary hospital in Taiwan. *PLoS One* 15: e0231413. doi:10.1371/journal.pone.0231413
- Yixin Yao, W.D., WHO, 2014. WHO | World Cancer Report 2014, Who. doi:10.4172/2157-2518.1000165.Genomic
- Yount, S., Beaumont, J., Rosenbloom, S., Cella, D., Patel, J., Hensing, T., Jacobsen, P.B., Syrjala, K., Abernethy, A.P., 2012. A Brief Symptom Index for Advanced Lung Cancer. *Clin. Lung Cancer* 13: 14–23. doi:10.1016/j.clcc.2011.03.033
- Zhou, Q., Yang, J.J., Chen, Z.H., Zhang, X.C., Yan, H.H., Xu, C.R., Su, J., Chen, H.J., Tu, H.Y., Zhong, W.Z., al., et, 2016. Serial cfDNA assessment of response and resistance to EGFR-TKI for patients with EGFR-L858R mutant lung cancer from a prospective clinical trial. *J. Hematol. Oncol.* 9: 86. doi:10.1186/s13045-016-0316-8